Allergic Contact Dermatitis Clinical Trial
Official title:
Epidemiology and Co-Reactivity of Novel Surfactant Allergens
The primary objectives of this study are to identify positivity rates to three novel surfactants (ingredients used in soaps, detergents, and other cleansers that serve to lower the surface tension of the skin and remove debris) and co-reactivity with other surfactants in patients with known surfactant sensitivity on skin patch testing. The investigators hypothesize that subjects who previously tested positive to known allergenic surfactants (cocamidopropyl betaine, stearamidopropyl dimethylamine, dimethylaminopropylamine, coconut diethanolamide, oleamidopropyl dimethylamine, and decyl glucoside) may demonstrate co-reactivity to the three novel surfactant sensitizers (sodium lauroyl sarcosinate, isostearmidopropyl morpholine lactate, and disodium lauroamphodiacetate) on skin patch testing.
Status | Completed |
Enrollment | 48 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Documentation of a previous contact allergy to one or more surfactant(s) on our screening series including: - cocamidopropyl betaine - stearamidopropyl dimethylamine - dimethylaminopropylamine - coconut diethanolamide - oleamidopropyl dimethylamine, and - decyl glucoside 2. Age 18 years or greater. Exclusion Criteria: 1. Pregnant or lactating women 2. Use of systemic therapy (corticosteroid, immunosuppressive agents, cytostatics, pentoxifylline, leukotriene antagonists or other medication known or suspected to have an effect of ACD) within two weeks prior to participation 3. Use of intramuscular steroids in the last month. 4. Phototherapy (PUVA or UVB) within two weeks prior to participation. 5. Direct sunlight or tanning booth use to the back within the two weeks prior to participation. |
Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Minneapolis Veterans Affairs Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with positive skin patch test reaction, scored using the North American Contact Dermatitis Group (NACDG) criteria, to three novel surfactant antigens. | NACDG Scoring as follows: 6=no reaction, 4=doubtful (faint erythema with no induration), 1= mild (erythema, induration, +/- papules), 2=moderate (erythema, induration, papules, vesicles), 3=severe (intense erythema, induration, coalescing vesicles, bullae, spreading), and 5= irritant. | Five days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03945760 -
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
|
Early Phase 1 | |
Not yet recruiting |
NCT05498467 -
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
|
Phase 3 | |
Active, not recruiting |
NCT03680131 -
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
|
Phase 2 | |
Recruiting |
NCT05535738 -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
|
Phase 2/Phase 3 | |
Recruiting |
NCT06191627 -
Patient Experience and Quality of Patch Testing on the Legs vs Back
|
N/A | |
Completed |
NCT00867607 -
Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT00445029 -
Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation
|
N/A | |
Completed |
NCT04365140 -
MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
|
||
Recruiting |
NCT05991674 -
A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
|
||
Completed |
NCT00931242 -
Study of Apremilast in Atopic or Contact Dermatitis
|
Phase 2 | |
Completed |
NCT01798589 -
Bioequivalence of Ethylenediamine Dihydrochloride Study
|
Phase 4 | |
Completed |
NCT01546298 -
Immune Reactions in Contact Dermatitis Affected Skin
|
||
Completed |
NCT05339750 -
Allergy Skin Patch Artificial Intelligence (AI)
|
N/A | |
Recruiting |
NCT03935971 -
The Effects of Dupilumab on Allergic Contact Dermatitis
|
Phase 4 | |
Completed |
NCT01797562 -
Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents
|
N/A | |
Not yet recruiting |
NCT05858723 -
Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool
|
N/A | |
Not yet recruiting |
NCT01413477 -
Nickel Desensitization Using Topical Therapy
|
N/A | |
Completed |
NCT00132600 -
Clinical Evaluation of Bacitracin
|
Phase 2 | |
Completed |
NCT00133341 -
Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate
|
Phase 2 | |
Completed |
NCT03902392 -
Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis
|
N/A |